Literature DB >> 2859066

Pharmacological analysis of beta-adrenoceptor-mediated agonism in the guinea-pig, isolated, right atrium.

J W Black, V P Gerskowitch, P Leff, N P Shankley.   

Abstract

The recently developed, operational model of pharmacological agonism defines the efficacy of agonists by tau = [Ro]/KE, where [Ro] is the total functional concentration of receptors and KE is the concentration of agonist-occupied receptors for half-maximal effect. Theoretically, variations in [Ro] and KE affect tau and in turn, E/[A] curve profiles similarly. Using the beta-adrenoceptor mediated chronotropic responses of the guinea-pig isolated right atrial preparation we have investigated the consequences of experimental [Ro] and KE variation. Bromoacetylalprenolol menthane (M-75) produced displacements of isoprenaline and dichloroisoprenaline E/[A] curves consistent with [Ro] reduction. Cholera toxin produced displacements consistent with decreases in KE. The operational model provides a simple conceptual framework for the prediction and interpretation of changes in E/[A] curve profile resulting from experimental interventions at the post-receptor (KE) level as well as at the receptor ([Ro]) level.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2859066      PMCID: PMC1987142          DOI: 10.1111/j.1476-5381.1985.tb16161.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  8 in total

1.  Cumulative dose-response curves. I. Introduction to the technique.

Authors:  J van ROSSUM; F van den BRINK
Journal:  Arch Int Pharmacodyn Ther       Date:  1963-05-01

2.  Effects of cholera enterotoxin on catecholamine-stimulated changes in cation fluxes, cell volume, and cyclic AMP levels in the turkey erythrocyte.

Authors:  S A Rudolph; D E Schafer; P Greengard
Journal:  J Biol Chem       Date:  1977-10-25       Impact factor: 5.157

3.  Mechanism of cholera toxin action: covalent modification of the guanyl nucleotide-binding protein of the adenylate cyclase system.

Authors:  D Cassel; T Pfeuffer
Journal:  Proc Natl Acad Sci U S A       Date:  1978-06       Impact factor: 11.205

4.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

5.  Regeneration of beta-adrenergic receptors in senescent rats: a study using an irreversible binding antagonist.

Authors:  J Pitha; B A Hughes; J W Kusiak; E M Dax; S P Baker
Journal:  Proc Natl Acad Sci U S A       Date:  1982-07       Impact factor: 11.205

6.  A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor.

Authors:  A De Lean; J M Stadel; R J Lefkowitz
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

7.  Irreversible blockade of beta adrenoreceptors and their recovery in the rat heart and lung in vivo.

Authors:  S P Baker; J Pitha
Journal:  J Pharmacol Exp Ther       Date:  1982-02       Impact factor: 4.030

8.  Mechanism of adenylate cyclase activation by cholera toxin: inhibition of GTP hydrolysis at the regulatory site.

Authors:  D Cassel; Z Selinger
Journal:  Proc Natl Acad Sci U S A       Date:  1977-08       Impact factor: 11.205

  8 in total
  9 in total

Review 1.  The recombinant 5-HT1A receptor: G protein coupling and signalling pathways.

Authors:  J R Raymond; Y V Mukhin; T W Gettys; M N Garnovskaya
Journal:  Br J Pharmacol       Date:  1999-08       Impact factor: 8.739

2.  Pharmacological analysis of the calcium-dependence of mu-receptor agonism.

Authors:  I G Dougall; P Leff
Journal:  Br J Pharmacol       Date:  1987-12       Impact factor: 8.739

3.  Pharmacological analysis of the interaction between Bay K 8644 and 5-HT in rabbit aorta.

Authors:  V J Barrett; P Leff; G R Martin; P J Richardson
Journal:  Br J Pharmacol       Date:  1986-03       Impact factor: 8.739

4.  Affinities of full agonists for cardiac beta-adrenoceptors calculated by use of in vitro desensitization.

Authors:  M L Herepath; K J Broadley
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-06       Impact factor: 3.000

5.  Desensitization and functional antagonism by beta-adrenoceptor and muscarinic receptor agonists, respectively: a comparison with receptor alkylation for calculation of apparent agonist affinity.

Authors:  R M Eglen; W W Montgomery; R L Whiting
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

6.  Modelling the changes induced by chronic desipramine treatment on the factors governing the agonism at prejunctional alpha 2-adrenoceptors.

Authors:  J Sallés; J Giraldo; E Vila; A Badia
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

7.  2-Naphthalenesulphonyl L-aspartyl-(2-phenethyl)amide (2-NAP)--a selective cholecystokinin CCKA-receptor antagonist.

Authors:  R A Hull; N P Shankley; E A Harper; V P Gerkowitch; J W Black
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  Thyroxine treatment of aged or young rats demonstrates that vascular responses mediated by beta-adrenoceptor subtypes can be differentially regulated.

Authors:  S R O'Donnell; J C Wanstall
Journal:  Br J Pharmacol       Date:  1986-05       Impact factor: 8.739

9.  Contrasts between pindolol and propranolol concentration-response relationships.

Authors:  S G Carruthers; W L Pacha; W H Aellig
Journal:  Br J Clin Pharmacol       Date:  1985-10       Impact factor: 4.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.